
Jean-Claude Tardif CM, MD, FRCPC, FCCS, FACC, FAHA, FESC, FCAHS
Director, MHI Research Center, Professor of Medicine, Canada Research Chair in translational and personalized medicine, University of Montreal endowed research chair in atherosclerosis, Montreal Heart Institute, Montreal, QuebecDisclosures
Disclosures: Dr. Tardif has received research grants from Amarin, AstraZeneca, DalCor, Esperion, Ionis, RegenXBio, Sanofi and Servier; honoraria from DalCor, HLS, Sanofi and Servier; holds minor equity interest in DalCor; and is an author of patents on pharmacogenomics-guided CETP inhibition and the use of colchicine after myocardial infarction.